Welcome to our dedicated page for KYOWA HAKKO KOGY UNSP/ADR news (Ticker: KYKOY), a resource for investors and traders seeking the latest updates and insights on KYOWA HAKKO KOGY UNSP/ADR stock.
Kyowa Kirin develops and commercializes specialty pharmaceuticals for rare and debilitating diseases, with reported activity in hematology-oncology, rare bone disease, immunology, and other therapeutic areas. News for KYKOY centers on clinical and scientific updates, collaboration activity, medical-conference presentations, and research partnerships tied to the company’s global pharmaceutical business.
Recurring developments include rocatinlimab, an investigational OX40 receptor-targeting T-cell rebalancing therapy studied in the ROCKET Phase 3 program for moderate to severe atopic dermatitis; burosumab research in X-linked hypophosphatemia; and collaboration activity involving ziftomenib in acute leukemias. Coverage also reflects Kyowa Kirin’s industry-academic immunology research relationships and its commercial and development roles across Japan, North America, and global markets.
Kyowa Kirin has announced board approval for a $530 million investment to build a new biologics manufacturing plant in Sanford, NC. This 171,700-square-foot facility will accelerate the production of new biologic therapies, especially for rare diseases, and create over 100 new jobs with an average salary of $91,496. The plant is expected to be operational by 2027 and will also contribute to the local economy. Supported by $10 million in state and local incentives over 12 years, the investment is projected to grow North Carolina's economy by $1.05 billion. The facility will be part of the Helix Innovation Park and will benefit from local biomanufacturing resources and specialized talent from nearby universities.
Kyowa Kirin Co., will present pre-clinical data at the Association for Research in Vision and Ophthalmology Annual Meeting 2024 regarding the use of nano-crystalized tivozanib eye drops for neovascular age-related macular degeneration (nAMD). The study showcases increased drug delivery efficiency to the retina/choroid compared to microcrystal formulations in animal models. This novel investigational agent has the potential to lessen the burden for patients with nAMD and diabetic macular edema (DME). Separate phase 2 clinical trials are ongoing to investigate the safety and efficacy of tivozanib eye drops in patients with nAMD and DME.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.